Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-01-22
2008-01-22
Kwon, Brian (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S393000, C514S397000, C514S249000
Reexamination Certificate
active
07320976
ABSTRACT:
Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.
REFERENCES:
patent: 3890319 (1975-06-01), Danielewicz et al.
patent: 4195085 (1980-03-01), Stone
patent: 4861760 (1989-08-01), Mazuel et al.
patent: 5856329 (1999-01-01), Wheeler et al.
patent: 6174524 (2001-01-01), Bawa et al.
patent: 6194415 (2001-02-01), Wheeler et al.
patent: 6248741 (2001-06-01), Wheeler et al.
patent: 6316441 (2001-11-01), Dean et al.
patent: 6410045 (2002-06-01), Schultz et al.
patent: 6440964 (2002-08-01), Cagle et al.
patent: 6441047 (2002-08-01), DeSantes, Jr.
patent: 6740664 (2004-05-01), Cagle et al.
patent: 2002/0128267 (2002-09-01), Bandyopadhyay et al.
Patient Information Brochure, “Brimonidine”, www.ausdi.com, 2000.
“Cardiovascular effects of timolol maleate, brimonidine or brimonidine/timolol maleate in comcomitant therapy”, Stewart et al., Acta Ophthalmologica Scandinavia, 2002, 80(3), 277-281.
“Aqueous humor flow in normal human eyes treated with brimonidine and timolol, alone and in combination”, Larrson, Lillinger, Archives of Ophthalmology, 2001, 119(4), 492-495.
“The short-term effect of adding brimonidine 0.2% to timolol treatment in patients with open-angle glaucoma”, Yuksel et al., Ophthalmologica, 1999, 213(4), 228-233.
“A short term study of the additive effect of timolol and brimonidine on intraocular pressure”, Arici et al., Eye, 2002, vol. 16, No. 1, pp. 39-43.
Sall et al., IOVS, 2001k, vol. 42, No. 4, pp. S822.
“Clinical Experience With Brimonidine 0.2% And Timolol 0.5% In Glaucoma And Ocular Hypertension”, Schuman, Survey of Ophthalmology, 1996, 41 Suppl 1 S27-37.
“Cardiovascular effects of timolol, brimonidine and brimonidine/timolol in combination”, Jackson et al., IOVS, vol. 42. No. 4, pp. S418.
“Aqueous humor flow in normal human eyes treated with brimonidine and timolol, alone and in combination”, Larson, IOVS, 1999, vol. 40, No. 4, pp. S515.
Hommer, A.B., et al.,Efficacy and Safety of Unoprostone, Dorzolamide, and Brimonidine in Adjunctive Therapy to Timolol in Patients with primary open-angle glaucoma and ocular hypertension, Investigative Ophthalmology & Visual Science, vol. 42, No. 4, Supp. Mar. 15, 2001, p. 554.
Hoyng, P.F., et al.,Pharmacological Therapy of glaucoma, Drugs, vol. 59, No. 3, Mar. 2000 pp. 411-434.
Larson, L.I.,Aqueous humor flow in normal human eyes trated with brimonidine and timolol, along and in combination, Arch Ophthalmol/ vol. 119, Apr. 2001, p. 492-495.
Schuman, J.S.,Clinical experience with brimonidine 0.2%and timolol 0.5%in glaucoma and ocular hypertension, Survey of Ophthalmology, vo. 41, Supp. 1, Nov. 1996, p. s27-s37.
Stewart, W.C.,Perspectives in the medical treatment of glaucoma, Current Opinion in Ophthalmology, vol. 10, No. 2, Apr. 1999, pp. 99-109.
Wang, R.F., et al.,Comparison of the ocular hypotensive effect of brimonidine, dorzolamide, latanoprost, or artificial tears added to timolol in glaucomatous monkey eyes, J. of Glaucoma 9:458-62.
Yukse,N., et al.,The short-term effect of adding brimonidine 0.2%to timolol treatment in patients with open-angle glaucoma, Ophthalmologica, vol. 213 (1999), pp. 228-233.
Craven et al, Efficacy and Safety of the IOP-Lowering Fixed Combination Brimonidine 0.2%/Timolol 0.5%, M200510403E.1.doc, one page, 2005.
Goni, “12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension”, European Journal of Ophthalmology, vol. 15, No. 5, 2005, pp. 581-590.
Batoosingh Amy L.
Beck Gary J.
Chang Chin-Ming
Pratt Cynthia C.
Allergan Inc.
Johnson Brent A.
Kwon Brian
Voet Martin A.
LandOfFree
Combination of brimonidine and timolol for topical... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination of brimonidine and timolol for topical..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination of brimonidine and timolol for topical... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2772597